Avadel Pharmaceuticals PLC (STU:AWK)
€ 9.85 0.4 (4.23%) Market Cap: 949.15 Mil Enterprise Value: 888.38 Mil PE Ratio: 0 PB Ratio: 13.32 GF Score: 40/100

Avadel Pharmaceuticals PLC Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study Transcript

Sep 23, 2019 / 01:00PM GMT
Release Date Price: €3.84 (+32.41%)
Operator

Greetings. Welcome to the Avadel Update Call.

(Operator Instructions) I'll now turn the conference over to Mike Kanan. Mike, you may now begin.

Michael F. Kanan
Avadel Pharmaceuticals plc - Senior VP & CFO

Thank you, and good morning, and thank you for joining us on our conference call.

This morning, we issued our press release announcing an agreement with the FDA to amend our FT218 Phase III REST-ON pivotal study that is under a special protocol assessment agreement with the FDA. The release can be accessed on our website at www.avadel.com.

As a reminder before we begin, the following presentation includes a number of matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot